These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21965433)

  • 21. Higher human T lymphotropic virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with HTLV-II subtype A versus B, and with male sex and a history of blood transfusion.
    Murphy EL; Lee TH; Chafets D; Nass CC; Wang B; Loughlin K; Smith D;
    J Infect Dis; 2004 Aug; 190(3):504-10. PubMed ID: 15243924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data.
    Kwaan N; Lee TH; Chafets DM; Nass C; Newman B; Smith J; Garratty G; Murphy EL;
    J Infect Dis; 2006 Dec; 194(11):1557-64. PubMed ID: 17083040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphisms at GLUT1 gene are not associated with the development of TSP/HAM in Brazilian HTLV-1 infected individuals and the discovery of a new polymorphism at GLUT1 gene.
    Costa GC; Azevedo R; Gadelha SR; Kashima SH; Muricy G; Olavarria VN; Covas DT; Takayanagui OM; Galvão-Castro B; Alcantara LC
    J Med Virol; 2009 Mar; 81(3):552-7. PubMed ID: 19152396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.
    Takenouchi N; Yamano Y; Usuku K; Osame M; Izumo S
    J Neurovirol; 2003 Feb; 9(1):29-35. PubMed ID: 12587066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers.
    Furukawa Y; Saito M; Matsumoto W; Usuku K; Tanaka Y; Izumo S; Osame M
    J Infect Dis; 2003 Apr; 187(7):1116-25. PubMed ID: 12660926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis.
    Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K
    Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study.
    Kira J; Koyanagi Y; Yamada T; Itoyama Y; Goto I; Yamamoto N; Sasaki H; Sakaki Y
    Ann Neurol; 1991 Feb; 29(2):194-201. PubMed ID: 2012389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].
    Carod-Artal FJ
    Rev Neurol; 2009 Feb 1-15; 48(3):147-55. PubMed ID: 19206063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
    Saito M; Nose H; Usuku K; Sabouri AH; Matsuzaki T; Izumo S; Arimura K; Osame M
    J Neurol Sci; 2006 Jul; 246(1-2):37-43. PubMed ID: 16545396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of host genetic and viral factors as surrogate markers for HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian HTLV-1-infected patients.
    Talledo M; López G; Huyghe JR; Verdonck K; Adaui V; González E; Best I; Clark D; Vanham G; Gotuzzo E; Van Camp G; Van Laer L
    J Med Virol; 2010 Mar; 82(3):460-6. PubMed ID: 20087941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis.
    Gabet AS; Mortreux F; Talarmin A; Plumelle Y; Leclercq I; Leroy A; Gessain A; Clity E; Joubert M; Wattel E
    Oncogene; 2000 Oct; 19(43):4954-60. PubMed ID: 11042682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir.
    Abad-Fernández M; Cabrera C; García E; Vallejo A
    J Clin Virol; 2014 Mar; 59(3):204-7. PubMed ID: 24457115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM.
    Cavrois M; Gessain A; Wain-Hobson S; Wattel E
    Oncogene; 1996 Jun; 12(11):2419-23. PubMed ID: 8649783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Quantitation of HTLV-I proviral copies of infected cells in pregnant HTLV-I carriers and its correlation with vertical infection].
    Tanigawa T
    Nihon Sanka Fujinka Gakkai Zasshi; 1994 Sep; 46(9):867-74. PubMed ID: 7963886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.
    Beilke MA; Traina-Dorge VL; Sirois M; Bhuiyan A; Murphy EL; Walls JM; Fagan R; Winsor EL; Kissinger PJ
    Clin Infect Dis; 2007 May; 44(9):1229-34. PubMed ID: 17407044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.
    Lehky TJ; Levin MC; Kubota R; Bamford RN; Flerlage AN; Soldan SS; Leist TP; Xavier A; White JD; Brown M; Fleisher TA; Top LE; Light S; McFarland HF; Waldmann TA; Jacobson S
    Ann Neurol; 1998 Dec; 44(6):942-7. PubMed ID: 9851439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Presence of HTLV-I proviral DNA in central nervous system of patients with HTLV-I-associated myelopathy.
    Kira J; Itoyama Y; Koyanagi Y; Tateishi J; Kishikawa M; Akizuki S; Kobayashi I; Toki N; Sueishi K; Sato H
    Ann Neurol; 1992 Jan; 31(1):39-45. PubMed ID: 1543349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitation of HTLV-I proviral load by a real-time PCR assay using SYBR Green: comparison of two methods for DNA isolation.
    Altamirano NA; Rocco C; Aulicino P; Sen L; Mangano A
    J Virol Methods; 2010 Dec; 170(1-2):160-4. PubMed ID: 20816699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low DNA HTLV-2 proviral load among women in São Paulo City.
    Montanheiro P; Olah I; Fukumori LM; Smid J; Oliveira AC; Kanzaki LI; Fonseca LA; Duarte AJ; Casseb J
    Virus Res; 2008 Jul; 135(1):22-5. PubMed ID: 18343520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.